Lentiviral vectors are the workhorse of ex vivo gene therapy — used to engineer T cells for CAR-T, TCR programs, and to modify hematopoietic stem cells for inherited disorders. Because the vector integrates into the genome of patient-bound cells, lentiviral manufacturing carries the regulatory weight of a critical starting material under full GMP, mandatory replication-competent lentivirus (RCL) testing, and BSL-2 containment throughout production.
Selecting a lentiviral vector CDMO comes down to five buyer-critical dimensions: BSL-2 containment maturity and site inspection history on lentivirus specifically, a scalable suspension (or well-run adherent) platform, qualified titer + potency + RCL assays, capacity headroom at your target dose × patient volume, and defensible tech-transfer support. The rankings below score each CDMO on FDA inspection classifications, EMA/MHRA GMP density, ClinicalTrials.gov sponsor breadth, and monitored capacity signals — a composite that reflects the regulatory record and operational depth needed for material that lands in patient-bound cells.
FDA inspection outcomes across these CDMOs: 1 NAI (no action), 1 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (18), Germany (3), United States (2), Italy (2).
Last updated 2026-07-11. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
#
CDMO
Signal Score
Quality
FDA · GMP
Capacity
Programs
1
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Lentivirus requires BSL-2 manufacturing with segregated suites and validated decontamination. Confirm the site's containment design and replication-competent lentivirus (RCL) testing strategy.
Process platform maturity
Suspension culture scales more cleanly than adherent for larger batches. Ask whether the platform is serum-free and how it performs at your target dose and patient volume.
Analytics & potency
Titer, infectivity, and potency assays drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both are shown in the rankings above and on each profile.
How does Japan's regenerative medicine regulatory framework affect cell and gene therapy CDMOs?
Japan operates one of the most developed advanced-therapy regulatory frameworks globally, distinguishing between three product classes with tailored requirements: regenerative medical products, cellular/tissue-based products, and gene therapy products. The framework's conditional and time-limited early approval pathway (introduced 2014, revised 2024) has accelerated advanced-therapy commercialization in Japan compared to most other markets. For CDMOs, this means Japanese advanced-therapy manufacturers have accumulated real experience with regulatory-supported early commercial supply — a signal that materially differs from the more restrictive US and EU pathways. Cross-reference with cell therapy, AAV, and cell & gene therapy umbrella pages for Japanese CDMO capability at the modality level.
PMDA regulatory posture — how does it compare to FDA and EMA?
PMDA GMP is generally regarded as tier-equivalent to FDA and EMA — inspections are rigorous, the framework is well-documented, and PMDA participates in the PIC/S mutual-recognition framework alongside EMA and other major regulators. For Japanese-manufactured product supplying US or EU markets, the qualifying signal is FDA or EMA inspection posture on the specific facility (not just PMDA certification), because FDA and EMA conduct their own facility inspections regardless of PMDA status. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly. Japanese CDMOs supplying global markets typically hold cross-jurisdictional certification.
Which Japanese CDMOs supply US and European markets?
The Japanese CDMOs with US and EU inspection posture typically operate global site networks or maintain FDA-inspected export facilities. Cross-check with the US region ranking and Europe region ranking to identify Japanese CDMOs appearing across regions — these have demonstrated multi-jurisdictional inspection posture. Individual profile pages surface facility-level detail on which specific Japanese sites carry which regulatory certifications.
By CDMO Signal's independent Signal Score, the top-ranked Lentiviral Vector CDMOs include AGC Biologics, Takara Bio. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Lentiviral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 1 Lentiviral Vector CDMO with FDA inspection records and 23 EMA/MHRA GMP certificates across the group.
What should I look for in a lentiviral vector CDMO?
Prioritize BSL-2 containment, a mature suspension platform, qualified titer/potency/RCL assays, and a clean FDA and EMA/MHRA record. Match capacity to your dose and patient volume, and confirm tech-transfer support.
How is lentiviral vector manufacturing different from AAV?
Lentivirus integrates into the host genome and is produced under BSL-2 with RCL testing, typically for ex vivo cell engineering. AAV is non-integrating, made at higher volumes, and used mainly for in vivo gene therapy.